ALIMTA

ALIMTA


You see the fact sheet Alimta in the following format: 100 mg powder for a solution for infusion Box of one vial of 100 mg of powder

Therapeutic class: Oncology and Hematology

Composition: Pemetrexed

Presentation: 100 mg Powder for a solution for infusion Box of one vial of 100 mg of powder

Indications Dosage Warnings against Interactions Precautions Side effects

- Malignant pleural mesothelioma:
ALIMTA in mixture with cisplatin is indicated for the healing of patients with malignant pleural mesothelioma whose disease is unrespectable and who have not up to that time received chemotherapy.
ALIMTA

- Non-small lung cancer cells:
  • ALIMTA in mixture with cisplatin is indicated for patients with non-small cell lung cancer, locally advanced or metastatic, when the histology is predominantly squamous-cell carcinoma.
  • ALIMTA is indicated as monotherapy for second-line treatment in patients with non-small cell lung cancer in locally advanced or metastatic, when the histology is not primarily squamous-cell carcinoma.